Batten Disease

Batten disease is the term used to describe the neuronal ceroid lipofuscinoses (NCLs), a group of rare, genetic, and neurodegenerative disorders that affect children and adolescents.

These are inherited conditions caused by mutations in different genes (including CLN1, CLN2, CLN3, and others). They are characterized by the accumulation of waste materials within the lysosomes of cells, leading to progressive degeneration of the central nervous system.

Among the various forms, one of the most common is the variant linked to the CLN3 gene, which represents the “classic” form of Batten disease. This form typically appears between the ages of 4 and 7 and initially manifests as progressive vision loss, which rapidly advances to blindness. Over time, additional symptoms develop, including epileptic seizures, motor and coordination difficulties, cognitive decline, and loss of language, with a significant impact on both quality of life and life expectancy.

Diagnosis is primarily based on genetic testing, supported by neurological and ophthalmologic evaluations, as well as instrumental examinations such as magnetic resonance imaging (MRI) and electroencephalography (EEG).

At present, there is no definitive cure for CLN3 Batten disease in Italy or Europe. Available treatments are symptomatic and supportive, aimed at improving the quality of life of the child and their family. These include antiepileptic medications, physical therapy, speech therapy, and psychological and educational support.

In recent years, however, research has opened new possibilities through the development of innovative therapeutic approaches. In particular, the experimental CLN301 gene therapy represents one of the most promising lines of investigation. This strategy uses an adeno-associated viral (AAV) vector to deliver a functional copy of the CLN3 gene into nerve cells, with the goal of compensating for the genetic defect and slowing disease progression. CLN301 is currently undergoing international clinical trials, and although results are still preliminary, it represents one of the most concrete hopes for the future of individuals affected by this condition. This is the path that HOPE4U INSIEME CONTRO BATTEN APS has chosen to pursue, in order to offer young Rachele the future she deserves.